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ClpP is a cylindrical serine protease whose ability to
degrade proteins is regulated by the unfoldase ATP-
dependent chaperones. ClpP on its own can only
degrade small peptides. Here, we used ClpP as
a target in a high-throughput screen for compounds,
which activate the protease and allow it to degrade
larger proteins, hence, abolishing the specificity
arising from the ATP-dependent chaperones. Our
screen resulted in five distinct compounds, which we
designate as Activators of Self-Compartmentalizing
Proteases 1 to 5 (ACP1 to 5). The compounds are
found to stabilize the ClpP double-ring structure.
The ACP1 chemical structure was considered to
have drug-like characteristics and was further opti-
mized to give analogs with bactericidal activity.
Hence, the ACPs represent classes of compounds
that can activate ClpP and that can be developed
as potential novel antibiotics.
INTRODUCTION
In recent years, there has been an alarming trend of increased
bacterial infections caused by strains resistant to most known
antibiotics. As a result, diseases that were thought to be
controlled by currently available drugs are re-emerging not
only in developing countries but also in industrialized nations,
especially in clinical settings such as hospitals. Therefore, thereChemistry & Biology 18, 1167–117is an urgent need for the development of new types of antibiotics
that can be used to effectively treat multidrug-resistant bacteria.
The development of new drugs with novel mechanisms of action
is clearly needed to avert an impending crisis.
Recently, a novel antibacterial target was identified when
Bro¨tz-Oesterhelt et al. (2005) discovered that the caseinolytic
protease P, ClpP, is activated by acyldepsipeptides, ADEPs,
a class of compounds that were first reported to have antibiotic
properties in 1985 (Michel and Kastner, 1985). The ADEPs were
later chemically optimized to address issues related to potency
and aqueous solubility (Hinzen et al., 2006). The protein target
of the ADEPs, ClpP protease, is a tetradecameric serine
protease comprised of two stacked heptameric rings, which, in
Escherichia coli, can form complexes with the AAA+ ATPase
chaperones ClpX or ClpA (Katayama et al., 1988; Maurizi and
Xia, 2004). ClpX and ClpA are hexameric chaperones that bind
on one or both ends of the ClpP protease. The chaperones
bind to target proteins, unfold them, and then thread them into
the ClpP proteolytic chamber through axial pores lined by axial
loops for degradation. These activities require ATP (Gottesman
et al., 1997). In the absence of the ATPase components, ClpP
alone can efficiently degrade small peptides of up to about 30
amino acids (Gottesman et al., 1997) and can also degrade
unstructured proteins albeit with much lower efficiency when
compared with ClpXP or ClpAP (Jennings et al., 2008; Bewley
et al., 2009). ADEPs enhance the efficiency of ClpP-dependent
degradation of unstructured proteins by opening up the ClpP
axial pores (Lee et al., 2010; Li et al., 2010).
The aforementioned studies demonstrated that ClpP is an
attractive target for developing new antibiotics with a novel
mode of action. In this study, we have identified, by using
a high-throughput screening approach, several structurally8, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1167
Figure 1. Results of the High-Throughput
Compound Screen for Activators of ClpP
(A) About 60,000 compounds were screened to find acti-
vators of E. coli ClpP. B-score values were calculated for
each compound from the increase in fluorescence inten-
sity after a 6 hour incubation of casein-FITC with ClpP and
compound. Compounds confirmed as hits, designated
ACP1 through ACP5, are indicated by the arrows (see also
Figure S1). Other compounds with high B-scores were
false hits.
(B) Shown are chemical structures of ACP1-ACP5 as
well as of ACP1a and ACP1b. ACP1 is N-1-[2-(phenylthio)
ethyl]-2-methyl-2-{[5-(trifluoromethyl)-2-pyridyl]sulfonyl}pro-
panamide, ACP2 is 3-(tertbutoxy)-2-{[2-[(5-(tertbutoxy)-2-
{[(9-H-9-fluorenylmethoxy)carbonyl]amino}-5-oxopentanoyl)
amino]-3-(tertbutylsulfanyl)propanoyl]amino}butanoic acid,
ACP3 is [4-(7-chloroquinolin-4-yl)piperazino](cyclohexyl)
methanone, ACP4 is ethyl 2-(2,2-dichlorovinyl)-4-hydroxy-
4-(3-nitrophenyl)-6-oxocyclohexanecarboxylate, and
ACP5 is ethyl 4-(4-bromophenyl)-2-(2,2-dichlorovinyl)-4-
hydroxy-6-oxocyclohexanecarboxylate.
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Activators of Self-Compartmentalizing Proteasesdiverse non-ADEP compounds that activate the ClpP proteolytic
core to degrade protein substrates in the absence of the ClpX
or ClpA ATPases. These newly identified compounds have
been termed Activators of Self-Compartmentalizing Proteases
(ACP). Their chemical structures differ significantly from the
structures of the previously identified ADEPs. The chemical opti-
mization of ACP1 resulted in analogs having improved bioactivity
and bactericidal effects. Hence, our study provides the basis for
the development of novel antibiotics based on the activation and
dysregulation of ClpP activity using different structural scaffolds.
RESULTS
High-Throughput Screen for ClpP Activators
To identify compounds that activate ClpP, we developed a high-
throughput screening assay with a fluorescence-based readout.1168 Chemistry & Biology 18, 1167–1178, September 23, 2011 ª2011 Elsevier Ltd AllThe assay employed fluorescein isothiocya-
nate-labeled casein (casein-FITC) as the
proteolytic target of the E. coli ClpP protease.
When casein-FITC is intact, FITC fluorescence
is quenched; protease-catalyzed hydrolysis of
casein-FITC relieves this quenching, yielding
highly fluorescent dye-labeled peptides. The
principle of the screen was to select for
compounds that result in increased fluores-
cence upon incubation of casein-FITC with
ClpP. Preliminary tests performed in the pres-
ence and absence of the unfoldase chaperone
ClpA revealed a 5-fold dynamic range after
30 min incubation and intra- and interassay
variability, expressed as coefficient of variation,
of 2% and 5%, respectively. In light of ClpP
stability over several hours at 37C, reactions
were typically monitored every 15 min for 6 hr
to rule out time-dependent effects.
With the initial intent of exploring drug-reposi-
tioning opportunities, we employed 4500 chem-
icals composed of biologically and pharmaco-logically active entities, of which approximately 45% were
marketed drugs or drug candidates evaluated in clinical trial
stages. Notably, none of these compounds were active at
a concentration of 10 mM, suggesting the necessity to signifi-
cantly broaden chemical diversity to explore ClpP druggability
and the likelihood to activate ClpP using small molecules.
Thus, we expanded the screening campaign to include addi-
tional 60,000 highly diverse, drug-like chemicals. This under-
taking was carried out using a final compound concentration of
20 mM. Results were normalized and corrected for systematic
errors using the B-scoremethod (Brideau et al., 2003) (Figure 1A)
and positive hits were defined as the compounds whose signals
were at least three standard deviations (99.73% confidence
interval) from the mean of the general sample population. An
excellent quality of the screening setup was shown by the
dimensionless parameters Z0- and Z-factors (Zhang et al.,rights reserved
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Figure 2. Relative Degradation Index
(A) Shown is the effect of compound concentration on casein-FITC degrada-
tion by ClpP after 6 hour incubation. Data are the average of three repeats.
Error bars represent standard deviations.
(B) Comparison of the RD25 values for the ACP compounds. Data shown
represent the average of three repeats. SD is standard deviation.
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Activators of Self-Compartmentalizing Proteases1999), which were consistently in the 0.7 range throughout the
entire screening campaign, thereby, indicating an effective
combination of dynamic range, variability, and hit rate.
This chemical screen led to the selection of five confirmed hits
(Figure 1B), that were designated ACP1 to 5. ACP1, ACP2, and
ACP3 were hits from the Maybridge library, while ACP4 and
ACP5 were hits from the Chembridge library. Interestingly,
ACP4 and ACP5 were analogous molecules, with identical
structures that only differed in the modification of an aromatic
group (Figure 1B).
Characterization of ACP-Mediated ClpP Activation
To assess and compare the potency of ACPs, dose-response
analyses were carried out following the degradation of casein-
FITC for 6 hours (Figure 2A). The results were evaluated using
a quantitative measure, which we developed and named the
relative degradation index (RD), defined as follows:
RD=

D4ClpP+ compound

after 6 hrs
D4ClpP

after 6 hrs
D4E:coli ClpAP

after 6 hrs
D4E:coli ClpP

after 6 hrs
: (1)
D4 is the change in fluorescence after 6 hr of starting the reac-
tion (see Experimental Procedures)measured using 485 nmexci-
tation and 535 nm emission, which primarily detects the signal
from casein-FITC. E. coli ClpAP was used as a benchmark for
maximum ClpP proteolytic activity. The ClpP in the numerator
can be from any other organism. Based on RD25measurements,
which refers to the measurement in the presence of 25 mM
compound, the ranking of the activators from strongest to weak-
est is as follows: ACP1, ACP5, ACP4, ACP2, and ACP3 (Fig-
ure 2B). It should be emphasized that the RD value reflects howChemistry & Biology 18, 1167–117much casein is degraded after 6 hr and, in theory, need not
directly correlate with the Kd for the binding of a given compound
to casein or with degradation rates, although, in practice, we
observe a general correspondence between these parameters.
The activation of ClpP by the various ACPs was further
confirmed by direct observation of unlabeled casein degradation
on SDS-PAGE gels (see Figure S1A available online), which also
indicated that the rank order of compound-mediated ClpP
activation was consistent with the observations obtained from
fluorometric determinations.
In order to verify that the activators were acting on ClpP rather
than on the casein substrate directly, the ability of compound-
activated ClpP to degrade proteins from various organisms
was tested using a variety of model substrates and unrelated
proteins (Figures S1B and S1C). The stronger activators induced
ClpP to degrade a wider variety of protein substrates than the
weaker activators with no apparent specificity. However, the
proteins subject to extensive proteolytic cleavage, such as
Casein (Creamer et al., 1981), Tah1 (Zhao et al., 2005), CFTR
R-region (Ostedgaard et al., 2001), reduced carboxymethylated
a-lactalbumin (RCMLa), lN protein (Mogridge et al., 1998),
and a-synuclein (Tompa, 2009) are either considered to be
unstable or disordered proteins or to have disordered regions.
Conversely, well-folded substrates, such as GFP-SsrA and crea-
tine kinase, were degraded to a lesser extent or not at all, likely
due to the stability of their structures. Proteins that were only
clipped, but not completely degraded, by compound-activated
ClpP (a-M protein, ClpA, and ClpX) were all larger sized proteins.
Chemical Optimization of ACP1
When tested for bactericidal properties against ten different
bacteria, several of the ACPs showed minimum bactericidal
concentrations (MBC in mg/ml) at relatively low concentrations
(Table 1). Although certain compounds were more effective
against some bacteria compared with others, it was generally
observed that gram-negative bacteria were more sensitive to
these compounds than gram-positives (Table 1).
To determine whether the effects observed were due to the
interaction of the ACPs with ClpP in the bacteria, we constructed
N. meningitidis H44/76 strain (Nme H44/76, a genetically trac-
table strain) in which the clpP gene was disrupted as described
in Experimental Procedures. The disruption of clpP was verified
by PCR (Figure S2A). The susceptibility of WT and DclpP Nme
H44/76 strains to the different compounds was assessed using
either the disk diffusion plate assay or the liquid culture MBC
assay. A differential effect was observed for ADEP1A and
ADEP1B (Figure S2B) in addition to ACP1 and, to a weaker
extent, ACP4 (not shown). For ACP1, the MBC for WT Nme
H44/76 was 128 mg/ml, while for DclpP it was 64 mg/ml. The
Nme H44/76 DclpP strain was more resistant to the effect of
the compounds compared with WT as would be expected
if the compounds are primarily targeting the bacterial ClpP.
These observations prompted us to implement medicinal
chemistry rationales aimed at the refinement and optimization
of primary hits.
The chemical structures of ACP1–5 (Figure 1B) do not show
any obvious structural similarities with each other, except for
ACP4 and 5, or with the ADEPs (Figure S2C). ACP4 and 5 were
considered to be unsuitable for further optimization as they do8, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1169
Table 1. Minimum Bactericidal Concentration of Compounds
PMBN
ADEP1A ACP1 ACP2 ACP3 ACP4 ACP5 ACP1a ACP1b
+  +  +  +  +  +  +  + 
N. gonorrhoeae
(N.279)
0.125a 0.125a >256 >256 32b 32b >256 >256 4a 4a >256 >256 128 >256 >256 >256
N. meningitidis
(MC58)
0.25a 0.25a 64b 64b >256 64b >256 >256 32b 32b >256 >256 64b 64b 16b 16b
H. influenzae
(H2192)
8a 128 64b >256 8a >256 >256 >256 4a 128 32b >256 32b >256 8a >256
E. coli (DH5a) 16b >256 >256 >256 8a >256 >256 >256 16b >256 16b >256 >256 >256 >256 >256
S. typhimurium
(SL1344)
>256 >256 >256 >256 >256 >256 >256 >256 >256 >256 >256 >256 >256 >256 >256 >256
P. aeruginosa
(PAO1)
16b >256 >256 >256 8a >256 >256 >256 >256 >256 >256 >256 >256 >256 >256 >256
S. aureus
(ATCC 29213)
N/A 4a N/A >256 N/A >256 N/A >256 N/A >256 N/A >256 N/A >256 N/A >256
S. pneumoniae
(ATCC 49619)
N/A 16b N/A >256 N/A 16b N/A >256 N/A 8a N/A >256 N/A N/A N/A N/A
L. monocytogenes
(EGD)
N/A 0.125a N/A >256 N/A 32b N/A >256 N/A >256 N/A >256 N/A N/A N/A N/A
M. smegmatis
(mc2155)
N/A >256 N/A >256 N/A >256 N/A >256 N/A 128 N/A 256 N/A >256 N/A >256
128 or more except where indicated with a footnote. The membrane permeabilizing agent polymyxin B nonapeptide, PMBN, was added at 120 mg/ml
where indicated.
a 0.125–8.
b 16–64.
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Activators of Self-Compartmentalizing Proteasesnot have drug-like structures and would be more challenging to
assess in a structure activity relationship (SAR) studies (Keller
et al., 2006). ACP2 would be relatively straightforward to eval-
uate in an SAR study, but the protected tripeptide derivative
framework was not considered optimal as a potential small-
molecule lead. Instead, ACP1 and 3 both display drug-like struc-
tures amenable to further optimization, synthesis, and SAR
studies. In light of the higher RD25 score for ACP1 (Figure 2B)
and the fact that it seems to indeed target ClpP in the cell as
described above, we decided to explore chemical diversity
around the ACP1 molecule.
ACP1 satisfies Lipinski’s rule of five (Lipinski et al., 2001) and
has a topological polar surface area of 75.6, calculated molar
refractivity of 10.4, and Clog P of 3.98. The structure of ACP1
consists of a central b-amido sulfone core appended with
a western electron deficient pyridyl ring and an eastern hydro-
phobic tail incorporating a phenylthioether group (Figures 1B
and 3A). The natural synthetic disconnection point chosen for
the synthesis of ACP1 analogswas the amide linkage (Figure 3A).
Analogs were synthesized using a late-stage amide-bond form-
ing reaction between the eastern amine and the western
b-sulfonyl carboxylic acid (Figure 3B) by applying standard
synthetic protocols (see Experimental Procedures) and, subse-
quently, evaluated by measuring their RD25 values. We used
the natural products ADEP1 factor A and B (Figure S2C) isolated
from Streptomyces hawaiiensis (see Experimental Procedures)
as a reference. ADEP1A is a better ClpP activator than ADEP1B
(Figure 3C).
Of more than 70 analogs generated, one compound, which we
termed ACP1b (Figure 1B), was found to exhibit an RD25 value1170 Chemistry & Biology 18, 1167–1178, September 23, 2011 ª201slightly higher than that of ADEP1A (Figure 3C). For comparison,
another analog, which we termed ACP1a (shown in Figure 1B),
displayed a lower RD25 value than that of ACP1b but compa-
rable to that of ADEP1B (Figure 3C). ACP1a incorporates a sulfur
to methylene substitution in the eastern tail, and ACP1b has an
ortho-chloro substituent in the arylthioether ring (Figure 1B).
The extent of casein degradation upon activation of ClpP by
these compounds is shown in Figure 3D and is generally consis-
tent with the RD25 results. It has previously been shown that
ADEPs activate E. coli ClpP to degrade casein with reduced
processivity (Bro¨tz-Oesterhelt et al., 2005; Kirstein et al., 2009).
This was also true for ACP1, ACP1a, and ACP1b (Figure 3E).
The patterns of appearance and disappearance of the degrada-
tion intermediates suggests similarities between the general
mechanisms of activation by the different compounds.
Notably, among the different bacterial species tested, ACP1b
showed an MBC value against H. influenzae that was compa-
rable to that of ADEP1A and much lower than that of ACP1
and ACP1a (Table 1). ACP1b also had improved MBC value
against N. meningitidis MC58 compared with ACP1 and
ACP1a, but not ADEP1A (Table 1). The MBC values for ACP1b
were 32 and 64 mg/ml for WT and DclpP Nme H44/76 described
above, respectively. Hence, while the WT is more sensitive to
ACP1b than the DclpP strain indicating that ClpP is indeed
a target for the compound in the cell, ACP1b might have other
cellular targets and further optimization will have to concentrate
on increasing specificity.
Although ACP1b was optimized against E. coli ClpP,
E. coli DH5a was resistant to this compound (Table 1), which is
consistent with earlier results (Bro¨tz-Oesterhelt et al., 2005).1 Elsevier Ltd All rights reserved
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Figure 3. Chemical Optimization of ACP1
(A) General chemical structure of the ACP1 analogs.
(B) A schematic of the chemical reaction to synthesize the ACP1 analogs using PyBoP mediated amide bond formation between 2-methyl-2-((5-(trifluoromethyl)
pyridin-2-yl)thio)propanoic acid and primary amines.
(C) RD25 values of ADEP1A, ADEP1B, ACP1–5, ACP1a, and ACP1b (see also Figure S2). Error bars represent the standard deviations from the average of three
repeats.
(D) Shown is the degradation of unlabeled casein by compound-activated ClpP followed on SDS-PAGE gels.
(E) The formation of intermediates during casein degradation by compound-activated ClpP.
Intermediate species, indicated by the parenthesis, resulting from casein degradation were resolved on 18% SDS-PAGE gels.
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Activators of Self-Compartmentalizing ProteasesBro¨tz-Oesterhelt et al. (2005) did not see an effect of ADEPs on
WT E. coli, but rather on an E. coli strain deleted of the multidrug
efflux pump AcrA in the presence of the outer membrane perme-
abilizer polymyxin B nonapeptide (PMBN). Hence, we combinedChemistry & Biology 18, 1167–117ACP1b with several other known drugs to enhance sensitivity.
Using this approach, ACP1b was found to affect cell growth of
E. coliMC4100 strain in the presence of 20 mM of the uncoupler
ionophore carbonyl cyanide 3-chlorophenylhydrazone (CCCP)8, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1171
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Figure 4. Determination of Binding Affinity of Compounds to ClpP
(A) ITC binding curves for ClpP-ADEP1A, ADEP1B, or ACP1b interaction are shown. Results for the fit of the data to a one set of identical independent binding site
model is given in the table. Numbers in parentheses refer to standard deviations. c2/DoF refers to chi-square divided by the degrees of freedom and indicates the
quality of the fit (see also Figure S3).
(B) Cooperativity of binding of ADEP1A and ACP1b to ClpP was determined bymeasuring the change in casein degradation rate by compound-activated ClpP as
a function of compound concentration. Error bars represent the standard deviations from the average of three repeats.
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Activators of Self-Compartmentalizing Proteases(FigureS2D). This sensitivitywasnot observed forMC4100DclpP
strain consistent with ClpP being a target for ACP1B in the cell.
The above observations indicate that the antibacterial proper-
ties of ACP1 can be improved through relatively simple chemical
modifications and that further efforts will have to concentrate on
enhancing specificity.
Determination of Binding Affinity and Stoichiometry
of ACP1b Interaction with ClpP
The dissociation constant (Kd) for the binding of ACP1b to ClpP
was measured using isothermal titration calorimetry (ITC) and
was found to be about 3.2 ± 0.5 mM, which is comparable to,
albeit slightly higher, than that of ADEP1A (0.3 ± 0.1 mM)
and ADEP1B (0.7 ± 0.2 mM) (Figure 4A). The ITC data were fit
by allowing the number of binding sites (n) to vary (Figure 4A),1172 Chemistry & Biology 18, 1167–1178, September 23, 2011 ª201by fixing n to a whole number (Figure S3A), or by fixing n to 14
(Figure S3B). The results suggest that there are 14 binding sites
for the ADEPs and ACP1b on ClpP14. In comparison, ACP1 has
a dissociation constant for ClpP of about 130 mM as determined
by Surface Plasmon Resonance (SPR) measurements (Fig-
ure S3C), whereas ITC was unsuitable to measure ACP1 affinity
for ClpP due to weak binding. The similar Kd values obtained for
the ADEPs by SPR (Figure S3C) and ITC (Figure 4A) clearly indi-
cate that ACP1 has lower affinity than the ADEPs for ClpP. SPR
experiments were also carried out for ACP2–5, and the Kd values
obtained were much weaker (>150 mM) than that of ACP1 as
expected (data not shown).
Measurement of casein degradation rate by compound-acti-
vated ClpP as a function of ADEP1A or ACP1b concentration re-
sulted in a sigmoidal saturation curve with S0.5 of 2–3 mM and1 Elsevier Ltd All rights reserved
AN
o
rm
al
ize
d 
c(S
)
0 200 400 600R
el
at
iv
e 
flu
or
es
ce
nc
e 
ch
an
ge
Time (s)
ClpPΔ31
ClpPΔ31
+ACP1
ClpPΔ31
+ACP1b
ClpPΔ31
+ACP1a
full length
ClpP
0
0.1
0.2
0.3
0.4
0.5
C
0
0.2
0.8
0.6
0.4
0 5 10 15 20
fu
ll l
en
gt
h 
Cl
pP
ClpP14
ClpP7
s20,w (S)
0.5
1.0
1.5
2.0
DMSO
ACP1
Cl
pP
Δ3
1
ClpPΔ3114
ClpPΔ317
2
3
1
ACP1b
4
5
ACP1a
6 70
9
10
Peak  
1 
2 
3 
4 
5 
6 
7 
9 
10 
8 
MW (kDa) 
134 
140 
277 
145 
297 
145 
282 
148 
303 
298 
Frictional ratio 
1.35780 
1.38695 
1.38695 
1.42471 
1.42471 
1.34795 
1.34795 
1.33438 
1.33438 
1.35871
s (S)
4.322 
4.353
6.860 
4.337 
7.000 
4.391 
7.250 
4.696 
7.587 
7.220 
7.307 
6.994 
10.943 
6.918 
11.167 
7.004 
11.564 
7.491 
12.103 
11.517 
ADEP1A
8
6
0
-6
0.5
5.9 6.0
0
6.1
no compound
Ab
so
rb
an
ce
 @
 2
80
 n
m
R
es
id
ua
ls
Radius (cm)
Kd = 8.59x10-4 M  
0.5
5.9 6.0
0
6.1
4
2
0
-2
-4
ACP1a
Ab
so
rb
an
ce
 @
 2
80
 n
m
R
es
id
ua
ls
Radius (cm)
Kd = 3.68x10-5 M  
4
2
0
-2
0.5
5.9 6.0 6.1
ACP1b
Radius (cm)A
bs
or
ba
nc
e 
@
 2
80
 n
m
R
es
id
ua
ls
Kd = 3.77x10-6 M  
0
B
ADEP1A
s20,w (S)
[(16.7-4.93)x10-4 M]
[(4.58-2.98)x10-5 M]
[(4.65-3.04)x10-6 M]
Figure 5. Effect of ACP on ClpP Oligomeric Stability
(A) Sedimentation velocity analytical ultracentrifugation of full length ClpP (46 mM) andClpPD31 (51 mM) at 4C shown using the continuous distributionmodel c(S)
versus s20,w, scaled to initial absorbance. ACP1, ACP1a, ACP1b, and ADEP1A (at 100 mM) promote the tetradecamerization of ClpPD31 to different extents. The
table lists the sedimentation coefficients, frictional ratios, and molecular weights corresponding to the various peaks.
(B) Sedimentation equilibrium profiles and the corresponding distribution of residuals for 51 mMClpPD31 in the absence of compound (top), or in the presence of
100 mM ACP1a (middle) or 100 mM ACP1b (bottom). The solid lines represent the best fit to a monomer-dimer model, with the heptameric ClpP (MW of 138,544
Da) treated as the monomer. The resulting dissociation constants are given for each data set. The numbers in brackets give the range of Kd values for the 95%
confidence interval.
(C) The effect of compounds (at 100 mM) on the peptidase activity of ClpPD31 (1 mM) is shown. The defective peptidase activity of thismutant is partially recovered
by the presence of the ACP compounds.
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Activators of Self-Compartmentalizing Proteasesa Hill coefficient, h, of about 4 (Figure 4B). The data suggest that
these compounds act on ClpP in a similar manner and bind to the
protease cooperatively or promote cooperative allosteric transi-
tions within the protease structure.
The ClpP Tetradecamer Is Stabilized by ACP Binding
Thermal melt experiments indicated that the ACP compounds
enhanced ClpP stability (not shown). Hence, we asked whether
the compounds affect ring-ring interactions within the ClpPChemistry & Biology 18, 1167–117double-ring tetradecamer. An N-terminal truncation mutant of
E. coli ClpP was originally constructed to open the central pore
of the protease in an attempt to mimic a proposed mechanism
of compound activation. However, this mutant, ClpPD31, mainly
eluted as a heptameric single ring upon size exclusion chro-
matography and had no significant peptidase activity. In order
to verify the oligomeric state of this protein, we employed sedi-
mentation velocity analytical ultracentrifugation (Figure 5A). The
results indicate that the ClpPD31 mutant has a sedimentation8, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1173
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WT ClpP has a sedimentation coefficient corresponding to a tet-
radecamer with a small proportion of heptamers (Figure 5A).
Addition of the different compounds shifts the oligomeric state
of ClpPD31 to that of a tetradecamer (Figure 5A). The proportion
of ClpPD31 tetradecamers formed correlates with the binding
affinity of the compounds. For example, ACP1b led to the forma-
tion of a higher proportion of tetradecamers than ACP1, while
ADEP1A led to the formation of the ClpPD31 tetradecamer
exclusively. It should be noted that integration of the normalized
c(S) signal over the s-values, which cover the range of sediment-
ingmaterial, shows that the total ‘‘loading signal’’ is similar for the
different curves with an average total loading signal of 0.52
(±0.12). The differences in the normalized c(S) peak heights is
mainly because some peaks are broader than others for the
various treatments of ClpPD31. Slight shifts in alignment of the
ClpPD31 tetradecamer sedimentation coefficient in the pres-
ence of the various compounds might indicate some disas-
sembly of the tetradecamer under the sedimentation velocity
nonequilibrium conditions or may be attributed to different
hydrodynamic properties of the tetradecamers formed. We
further verified the oligomeric state of the ClpPD31 in the pres-
ence of ACP1a or ACP1b using sedimentation equilibrium exper-
iments (Figure 5B). Fits of the data to monomer-dimer equilib-
rium, assuming the monomer is heptameric ClpPD31 with a
molecular weight of 138,544 Da, clearly indicate that the pres-
ence of ACP1a or ACP1b decreases the dissociation constant
of the ClpP tetradecamer with ACP1a having a lower Kd than
ACP1b, which, in turn, is lower than that in the absence of the
compound (Figure 5B).
Without the addition of compound, ClpPD31 had little
protease activity (Figure 5C). Addition of ACP1, ACP1a,
ACP1b, or ADEP1A promoted the formation of tetradecameric
ClpPD31 (Figures 5A and 5B) and resulted in a catalytically active
ClpPD31 (Figure 5C). These results strongly suggest that the
ACP compounds stabilize ClpP by promoting the formation of
the double-ring structure.
ACP Binding Sites on ClpP
The ADEPs have been found to bind in a hydrophobic pocket (H
pocket) on the ClpP apical surface in which the IGF loop of the
ClpX/ClpA ATPases also binds (Lee et al., 2010; Li et al.,
2010). As a result, the presence of the ADEPs inhibited or
reduced the ClpXP/ClpAP-mediated degradation of GFP-ssrA
by interfering with the binding of ClpX/ClpA to ClpP. As shown
in Figure 6A and Figure S4A, a similar effect was also seen for
the ACPs suggesting that these compounds either bind to or
allosterically modulate the H pocket of ClpP.
Two binding pockets on ClpP of equal probability were pre-
dicted by computational procedures implemented in DOCK6.3
software (Lang et al., 2009) (see Experimental Procedures; Fig-
ure 6B; Table S1), namely, the H pocket and a separate pocket,
which we have named the C pocket, featuring a larger number of
charged residues. The H pocket is composed of residues V42,
F44, L62, Y74, Y76, I104, F126, L203, and R206 from one
subunit, and L37 and F96 from the neighboring subunit (using
Swiss-Prot numbering). The C pocket comprises residues Y90,
M94, Q95, D100, V101, and H170 of one subunit and residues
H205 and N207 of the neighboring subunit. Interestingly, the H1174 Chemistry & Biology 18, 1167–1178, September 23, 2011 ª201and C pockets are separated by residues at the very C terminus
of ClpP, corresponding to amino acids 203–207. While ADEPs
cocrystallized with ClpP were found to be bound to the H pocket
(Lee et al., 2010; Li et al., 2010), all the ACP compounds
were docked well to both the H and C pockets (Figure 6B), and
their docking scores differed little between the two pockets
(Table S1).
To further validate the results of the docking analyses, we
generated and tested mutants of the H pocket (Y76W [Lee
et al., 2010], F126A [Bewley et al., 2006], and L203E), C pocket
(Q95A, D100A, and H170A), as well as both the H and C pockets
(Figure 6B). Peptidase assays were first performed to assess
whether the mutations affected ClpP active sites. Except for
Y76W, H170A, and Q95A/F126A, the mutants exhibited pepti-
dase activity similar to that of the wild-type (WT) protein (Fig-
ure S4B). Intriguingly, we observed that the effects of stronger
ClpP activators, such as ADEP1A and ACP1b, markedly de-
creased in the presence of mutations confined to the H pocket,
whereas weaker activators appeared to be affected by muta-
tions in both H and C pockets (Figure 6B). These findings, taken
together, suggest that a successful strategy aimed at developing
stronger ClpP activators is that of developing small molecules
interacting with ClpP within the H pocket.
DISCUSSION
In our study, we have successfully identified five new com-
pounds representing four different structural classes (Figure 1B)
that activate ClpP protease and have bactericidal properties.
With the exception of ACP4 and ACP5, these compounds have
no apparent structural similarities to each other or to the previ-
ously reported ADEPs (Bro¨tz-Oesterhelt et al., 2005), dramati-
cally increasing the repertoire of compounds activating this
protease. The optimization of ACP1 resulted in compounds
that had in vitro ClpP activation properties close to that of the
natural product ADEPs (Figure 3C). Importantly, these optimized
compounds have good bactericidal properties (Table 1), sug-
gesting potential applications as therapeutics. In particular, our
data indicate that these compounds may be dramatically
improved through a much tighter affinity for ClpP and specific
targeting within the ClpP H pocket.
Based on the results of Figures 4–6, we propose that the iden-
tified ACP compounds share a similar mechanism of ClpP acti-
vation as the ADEPs. They all stabilize ClpP and promote the
formation of the double-ring structure, albeit through a yet
unknownmechanism. The apparent lack of substrate preference
(Figures S1B and S1C) that the compounds confer on ClpP in
addition to the similarities in degradation patterns (Figure 3E) is
also indicative of similarities in mechanism of ClpP activation.
The compounds prevent the binding of ClpP to its associated
unfoldase (Figure 6A; Figure S4A) and, at the same time, activate
nonspecific proteolysis probably through the opening of the
axial pores.
The recently solved cocrystal structures of ADEP bound to
B. subtilis and E. coli ClpP (Lee et al., 2010; Li et al., 2010)
show ADEP binding to the H pocket of the protease. Our results
are in general agreement with these findings; however, we
propose the presence of an additional pocket, the C pocket,
that is more charged (Figure 6B) and, as suggested by our1 Elsevier Ltd All rights reserved
Figure 6. ACP Binding Sites
(A) Shown is the inhibition of ClpXP-mediated GFP-ssrA degradation by ACPs and ADEPs added at 100 mM monitored on SDS-PAGE gels. ClpP was
preincubated with compound before the addition of ClpX (see also Figure S4A).
(B) Surfacemodel of ClpP is shown on the top left. Four neighboring subunits are colored in alternating blue and green. The H pockets are colored in purple, while
the C pockets are colored in yellow. The bottom left panel shows a close up view of the predicted compound binding conformations in the two ClpP pockets. The
five ACP compounds are overlaid in the binding pockets (see also Table S1). ClpP is shown as a surfacemodel and the compounds are shown as stick models. C,
N, O, S, F, Cl, Br, and H in the compounds are colored in gray, blue, red, yellow, cyan, green, purple, and white, respectively. The ClpP surface is colored
according to the electrostatic surface potential and ranges from red (potential of 4kT) to blue (potential of +4kT) calculated using DelPhi (Rocchia et al., 2002).
Also shown on the right panels are stickmodels of ACP1 docked into the H and C pockets of ClpP drawn as ribbons colored by chain. For ACP1, C, N, O, S, F, and
H are colored in orange, blue, red, yellow, cyan, and white, respectively. All molecular graphics figures were prepared using the program PyMOL.
(C) Effect of mutations in the H and C pockets on ClpP activation by compounds measured using RD25. Data shown represent the average of three repeats and
error bars give the standard deviations on the measurements (see also Figure S4B).
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Activators of Self-Compartmentalizing Proteasesmutational analysis, involved in compound binding (Figure 6C). It
is likely that the binding of compounds in the H pocket mimics
the binding of ATPase chaperones and causes conformational
changes in the ClpP axial pore, which normally occur upon
binding of the Clp ATPase. The ADEP compounds, being much
larger and bulkier, make more contacts in the ClpP binding
pocket than the ACPs. The ACP compounds make fewer
contacts, yet still induce ClpP activation. How these dissimilar
compounds can cause the same effects warrants further inves-
tigation. Cocrystallization trials are currently under way to gain
further understanding of the interaction of these compounds
with ClpP.
In summary, our study identified new activators of ClpP that
we term ACPs. These activators can be purchased relatively
cheaply from regular vendors allowing any group to study this
phenomenon without the need to rely on difficult purification
procedures of natural products or complicated chemical
synthesis methods. We expect that activators of self-compart-
mentalizing proteases will be important players in future drug
development efforts.
SIGNIFICANCE
With the rise of antibiotic-resistant bacteria, there is an
urgent need for the development of new compounds having
novel mode of function. The ability to dysregulate ClpP
serine protease activity represents a novel approach for
the development of new antibacterials. ClpP activity is
tightly regulated by bound ATPase chaperones. These
ATPases typically form hexameric rings that bind on one or
both ends of the ClpP double-ring cylinder. The ATPases
select target substrates, which are then unfolded and
threaded through the ATPase ring and into the ClpP cylinder
for degradation. Threading into the ClpP proteolytic
chamber occurs through narrow axial pores that do not
allow structured proteins to pass, hence, the requirement
for protein unfolding. Acyldepsipeptides, ADEPs, were
recently found to bind ClpP and open the axial pores of the
protease allowing ClpP to degrade folded proteins indepen-
dent of its chaperone resulting in unregulated degradation
of protein substrates. ADEPs were found to have antibacte-
rial activity and were originally purified from Streptomyces.
However, the chemical synthesis of these compounds is
quite challenging. In order to identify novel compounds
that activate ClpP, we used a high-throughput screening
approach with a fluorescence-based readout. The assay
employed fluorescein isothiocyanate-labeled casein as the
proteolytic target of the Escherichia coli ClpP protease.
Five structurally diverse compounds were identified to acti-
vate ClpP that we named Activators of Self-Compartmental-
izing Proteases 1 to 5 (ACP1–5). Their chemical structures
differ significantly from the structures of the ADEPs. The
chemical optimization of ACP1 resulted in analogs having
improved bioactivity and bactericidal effects. The com-
pounds were found to stabilize the ClpP double-ring struc-
ture and to bind in pockets on the ClpP apical surface.
Hence, our study provides the basis for the development
of novel antibiotics based on the activation and dysregula-
tion of ClpP activity using different structural scaffolds.1176 Chemistry & Biology 18, 1167–1178, September 23, 2011 ª201EXPERIMENTAL PROCEDURES
Protein Expression and Purification
All proteins were expressed from IPTG inducible promoters. ClpP constructs
were expressed in BL21(DE3)1146D strain, which lacks the gene for chromo-
somal E. coli ClpP. All other constructs were expressed in BL21(DE3)Gold
(Stratagene). Untagged WT and mutant E. coli ClpP, ClpX, and GFP-SsrA
were expressed and purified as previously described (Wojtyra et al., 2003).
ClpA was expressed and purified as described in Lo et al. (2001). All His-
tagged proteins were purified on Ni-NTA agarose resin (QIAGEN) according
to the manufacturer’s protocols. If possible, the tag was removed using the
tobacco etch virus (TEV) protease. Protein concentrations were determined
by absorbance at 280 nm with extinction coefficients calculated using
ProtParam (http://ca.expasy.org/tools/protparam.html).
Tah1 (Zhao et al., 2008) and lO (Wojtyra et al., 2003) were purified as
previously described. pHF010 plasmid encoding H6-lN was a kind gift from
Dr. Irene Lee (Case Western Reserve University) and the protein was purified
according to published protocols (Patterson-Ward et al., 2009). CFTR
R-domain and a-synuclein were gifts from Dr. Julie Forman-Kay (University
of Toronto). The Neisseria a-M protein was from Mr. Shekeb Khan from
EFP’s group. Reduced carboxymethylated a-lactalbumin was a gift from
Dr. John Glover (University of Toronto). Creatine kinase, a-casein, casein
fluorescein isothiocyanate (casein-FITC, type II, 20–50 mg FITC/mg, catalog
number C3777), and N-Succinyl-Leu-Tyr-7-amido-4-methylcoumarin (Suc-
LY-AMC) were purchased from Sigma-Aldrich.
Chemical Libraries and High-Throughput Screening
The libraries employed for the screening campaigns were composed of exper-
imental bioactives, pharmacologically active chemicals and natural products,
off-patent marketed drugs, and small molecules with drug-like properties.
Samples were obtained from the following, commercially available collections:
LOPAC 1280 (Sigma, 1280 samples), Prestwick Chemical library (Prestwick
Chemical, France, 1120 samples), SPECTRUM collection (MicroSource,
2000 samples), Maybridge Screening collection (Maybridge-Thermo Fisher
Scientific, UK, 50,000 samples), and Chembridge DIVERSet (ChemBridge
Corp, 10,000 samples). In all instances, samples stored in 384-well plates as
1 or 5 mM solutions in 100% DMSOwere transferred to assay plates in a fixed
volume of 200 nl by a pin-tool (V&P Scientific). Screens were conducted using
a fully automated procedure run on a DIM4 flipmover platform (Thermo Elec-
tron Corp) equipped with a Biomek FX liquid handler (Beckman, USA) and
a PHERAStar detection system (BMG Labtech, Germany). The reaction for
the screening assay contained 20 mM compound, 3.6 mM ClpP, and 4.5 mM
casein-FITC in buffer A (25 mM Tris HCl [pH 7.5], and 100 mM KCl) at 37C.
Compounds thatwere identified andconfirmed tobe hitswere obtained from
the following companies: ACP1, ACP2, and ACP3 are from Maybridge (May-
bridge, Thermo-Fisher Scientific, catalog number BTB09142, JFD02943, and
KM11066, respectively); ACP4 and ACP5 are from Chembridge (ChemBridge
Corporation, catalog number 5107477 and 5107473, respectively).
Activity Assays
To measure the RD index, each reaction consisted of 3.6 mMClpP and a spec-
ified amount of compound in buffer A. The reactions were preincubated for
10 min at 37C before 4.5 mM casein-FITC and 15.5 mM unlabeled casein
were added. ClpAP-dependent degradation of the same casein-FITC
substrate was used as a control. Each ClpAP reaction contained 3.6 mM
ClpP, 3 mM ClpA, and 0.3 mM ATP in buffer B (25 mM HEPES [pH 7.5],
20 mM MgCl2, 30 mM KCl, 0.03% Tween 20, and 10% glycerol), and an
ATP-regenerating system (13 units/ml of creatine kinase and 16 mM creatine
phosphate). The reaction was started by adding casein-FITC. Reactions
were incubated at 37Cand the fluorescence (485 nmexcitation, 535 nmemis-
sion) was monitored every 15 min for 6 hr on a PHERAStar detection system.
Casein-FITC degradation by compound-activated ClpP after 6 hr at 37C was
compared with the ClpAP-dependent casein-FITC degradation after 6 hr at
37C, using Equation 1.
The effects of the compounds on the degradation of GFP-ssrA by ClpXP
were also analyzed on SDS-PAGE gels. Each reaction contained 1.2 mM
ClpP, 3.9 mM GFP-ssrA, 3 mM ATP, and 100 mM compound in buffer C
(25 mM HEPES [pH 7.5], 5 mM MgCl2, 5 mM KCl, 0.03% Tween 20, and1 Elsevier Ltd All rights reserved
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preincubated for 3 min at 37C before 1 mM ClpX was added. Samples were
taken at various time points, stopped by boiling in 2% SDS, and resolved on
12% SDS-PAGE gels.
Peptidase activity of ClpP was measured by the ability of ClpP to cleave the
dipeptide Suc-LY-AMC. Each reaction contained 1 mMClpP in buffer D (50mM
Tris HCl [pH 8], 200 mM KCl, and 1 mM DTT). ClpP was incubated for 3 min at
37Cbefore Suc-LY-AMCwas added to a final concentration 0.5mM. Fluores-
cence (350 nmexcitation, 460 nm emission) of the released AMCwas detected
on the PHERAStar system.
For the Hill plot analysis of Figure 4B, each reaction consisted of 3.6 mMClpP
and specified amount of compound in buffer A. The reactions were pre-incu-
bated for 10 min at 37C before 4.5 mM casein-FITC was added. Reactions
were incubated at 37Cand the fluorescence (485 nmexcitation, 535 nmemis-
sion) was monitored every 3 s for 5 min on an EnSpire Multilabel Plate Reader
(PerkinElmer).
N. meningitidis H44/76 clpP Insertional Mutagenesis
To construct the N. meningitidis H44/76 clpP insertional mutant vector, desig-
nated Nme-clpP-ery, primers f2 and r2 shown in Figure S2A were used to
amplify a fragment of the genome that contained the clpP gene and the result-
ing PCR fragment was cloned into the pTrc99A vector. Using the f3 and r1
primers (Figure S2A), an erythromycin cassette with EagI ends was amplified
from the pFLOB4300 vector (Litt et al., 2000) and the resulting PCR fragment
was cloned into the EagI restriction site located at the 50 end of the clpP gene
within the Nme-clpP vector. The N. meningitidis H44/76 clpP insertional
mutant was generated by transforming WT N. meningitidis H44/76 with the
Nme-clpP-ery vector using an electroporation protocol adapted from (Dillard,
2006). PCR verification of the mutant strain is shown in Figure S2A.
Determination of Minimum Bactericidal Concentrations
Bacterial strains used included both gram-negative and gram-positive
bacteria: Escherichia coli DH5a, Salmonella typhimurium SL1344,
Pseudomonas aeruginosa PAO1, Haemophilus influenzae H2192, Neisseria
gonorrhoeae N.279, Neisseria meningitidis H44/76, Neisseria meningitidis
MC58, Staphylococcus aureus ATCC 29213, Streptococcus pneumoniae
ATCC 49619, and Listeria monocytogenes EGD. Due to the lowwater solubility
of the ADEP and ACP compounds, minimum bactericidal concentrations
(MBC) values were determined by plating compound-treated bacteria on
agar plates without compound. All compounds were diluted in Brain Heart
Infusion (BHI) medium with 1% Isovitale X (Becton Dickinson). All bacteria
were also inoculated into BHI. A 2-fold dilution series of each compound
was created in 96-well plates, with and without 120 mg/ml of the membrane
permeabilizing agent polymyxin B nonapeptide, PMBN (Sigma-Aldrich) (Ofek
et al., 1994; Tsubery et al., 2002). All bacterial suspensions were pelleted,
resuspended in BHI, and added to the compound containing media.
H. influenzae, N. gonorrhoeae, and N. meningitidis were incubated 18–20 hr,
while the remaining strains were incubated 12 to 16 hr. H. influenzae,
N. gonorrhoeae, N. meningitidis, and S. pneumoniae were incubated in the
presence of 5% CO2. 2 ml of culture from the incubations were then plated
onto compound-free agar plates (H. influenzae, N. gonorrhoeae,
N. meningitidis for 18–20 hr; remaining strains for 12–16 hr) to determine the
bactericidal activity. H. influenzae was grown on chocolate agar;
N. gonorrhoeae on GC agar base; N. meningitidis, S. aureus, and
L. monocytogenes on BHI agar; S. pneumoniae on 5% sheep blood agar;
and E. coli, S. typhimurium, and P. aeruginosa on LB agar. The lowest concen-
tration of compound at which no bacterial growth was seen was designated as
the minimum bactericidal concentration.
Antimycobacterial activities of the ClpP activating compounds were investi-
gated using the 96-well plate broth microdilution method modified from
Wallace et al. (1986), followed by plating for viable bacteria. Compounds
were dissolved in 100% DMSO. M. smegmatis mc2155 cultures were grown
to an OD600 of 1.0–1.3 in Middlebrook 7H9 broth (Difco, BD Biosciences)
supplemented with 2% oleic acid, albumin, dextrose, and catalase (OADC
enrichment, BD Biosciences) as well as 0.2% glycerol and 0.5% Tween 80
to avoid clumping of bacteria. Cultures were then diluted 10-fold and 5 ml
were used to inoculate 100 ml of a 2-fold dilution series of compounds in the
range of 1 mg/ml to 256 mg/ml in 7H9 broth supplemented with OADC andChemistry & Biology 18, 1167–1170.2% glycerol in the presence or absence of 12.5 mg/ml polymyxin B. Poly-
myxin B is known to enhance mycobacterial permeability to hydrophobic
compounds (Korycka-Machala et al., 2001). The solvent control, DMSO at
2% or less, showed no inhibitory effects on M. smegmatis growth. Plates
were incubated in a CO2 incubator for 8 days. Following incubation, dilutions
of sample aliquots were spread onMiddlebrook 7H11 plates (Difco, BD Biosci-
ences) supplemented with 2% OADC and 0.5% glycerol for determination of
bacterial viability.
Monitoring of E. coli Growth in the Presence of ACP Compounds
The E. coli strains used for growth curves shown in Figure S2D, MC4100 and
MC4100 DclpP::cat, were grown overnight in LB and then diluted into fresh LB
to OD600 of 0.02. One hundred microliters of the diluted cell culture was added
to 100 ml of LB containing ACP1b and CCCP (carbonyl cyanide 3-chlorophe-
nylhydrazone) (Sigma-Aldrich). Final concentrations were 128 mg/ml ACP1b
and/or 20 mM CCCP. The solvent control cultures contained 20 mM CCCP
and 2.2% DMSO in place of ACP1b. Growth was monitored overnight at
30C in a Bioscreen-C incubator system (Growth Curves, USA).
Other Procedures
Additional methods are given in the Supplemental Experimental Procedures,
namely, subcloning and mutagenesis, surface plasmon resonance measure-
ments, isothermal titration calorimetry measurements, analytical ultracentrifu-
gation measurements, thermal denaturation of ClpP, isolation of ADEP1A and
ADEP1B from Streptomyces hawaiiensis NRRL 15010, docking procedure,
and chemical synthesis of ACP1 and analogs.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.chembiol.2011.07.023.
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